Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients

To date, only few data concerning the biologically active, free form of testosterone (FT) are available in metastatic prostate cancer (mPC) and the impact of FT on disease, therapy and outcome is largely unknown. We retrospectively studied the effect of docetaxel on FT and total testosterone (TT) se...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2021-08, Vol.11 (1), p.16457-16457, Article 16457
Main Authors: Kappler, Paula, Morgan, Michael A., Ivanyi, Philipp, Brunotte, Stefan J., Ganser, Arnold, Reuter, Christoph W. M.
Format: Article
Language:English
Subjects:
631/67
631/67/589/466
Androgen receptors
Biological activity
Humanities and Social Sciences
Medical prognosis
Metastases
Metastasis
multidisciplinary
Narcotics
Patients
Prostate cancer
Prostate-specific antigen
Science
Science (multidisciplinary)
Serum levels
Survival
Testosterone
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To date, only few data concerning the biologically active, free form of testosterone (FT) are available in metastatic prostate cancer (mPC) and the impact of FT on disease, therapy and outcome is largely unknown. We retrospectively studied the effect of docetaxel on FT and total testosterone (TT) serum levels in 67 mPC patients monitored between April 2008 and November 2020. FT and TT levels were measured before and weekly during therapy. The primary endpoint was overall survival (OS). Secondary endpoints were prostate-specific antigen response and radiographic response (PSAR, RR), progression-free survival (PFS), FT/TT levels and safety. Median FT and TT serum levels were completely suppressed to below the detection limit during docetaxel treatment (FT: from 0.32 to 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-95874-y